Cargando…

Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance

BACKGROUND: Misfolded oligomeric α-synuclein plays a pivotal role in the pathogenesis of α-synucleinopathies including Parkinson’s disease and multiple system atrophy, and its detection parallels activation of microglia and a loss of neurons in the substantia nigra pars compacta. Here we aimed to an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lemos, Miguel, Venezia, Serena, Refolo, Violetta, Heras-Garvin, Antonio, Schmidhuber, Sabine, Giese, Armin, Leonov, Andrei, Ryazanov, Sergey, Griesinger, Christian, Galabova, Gergana, Staffler, Guenther, Wenning, Gregor Karl, Stefanova, Nadia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513530/ https://www.ncbi.nlm.nih.gov/pubmed/32972456 http://dx.doi.org/10.1186/s40035-020-00217-y

Ejemplares similares

Anle138b modulates α‐synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy
por: Heras‐Garvin, Antonio, et al.
Publicado: (2018)

Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy
por: Fellner, Lisa, et al.
Publicado: (2016)

The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils
por: Antonschmidt, Leif, et al.
Publicado: (2022)

The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset
por: Levin, Johannes, et al.
Publicado: (2014)

Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies
por: Wagner, Jens, et al.
Publicado: (2015)

High-salt diet does not boost neuroinflammation and neurodegeneration in a model of α-synucleinopathy
por: Heras-Garvin, Antonio, et al.
Publicado: (2020)

Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau
por: Brendel, Matthias, et al.
Publicado: (2019)

The small molecule inhibitor anle145c thermodynamically traps human islet amyloid peptide in the form of non-cytotoxic oligomers
por: Saravanan, Manikam S., et al.
Publicado: (2019)

Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease
por: Wagner, Jens, et al.
Publicado: (2013)

The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology
por: Martinez Hernandez, Ana, et al.
Publicado: (2017)

(11)C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson's Disease That Binds to α‐Synuclein Fibrils in vitro and Crosses the Blood‐Brain Barrier
por: Maurer, Andreas, et al.
Publicado: (2020)

Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial
por: Levin, Johannes, et al.
Publicado: (2022)

Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy
por: Venezia, Serena, et al.
Publicado: (2017)

Synthesis and Preliminary Characterization of Putative Anle138b-Centered PROTACs against α-Synuclein Aggregation
por: Pedrini, Martina, et al.
Publicado: (2023)

Therapeutic Trial of anle138b in Mouse Models of Genetic Prion Disease
por: Vallabh, Sonia M., et al.
Publicado: (2023)

In Silico Study of the Interactions of Anle138b Isomer, an Inhibitor of Amyloid Aggregation, with Partner Proteins
por: Kondratyev, Maxim S., et al.
Publicado: (2022)

Mechanism of action deconvolution of the small-molecule pathological tau aggregation inhibitor Anle138b
por: Hosseini-Gerami, Layla, et al.
Publicado: (2023)

Neuroinflammation and Glial Phenotypic Changes in Alpha-Synucleinopathies
por: Refolo, Violetta, et al.
Publicado: (2019)

From Synaptic Protein to Prion: The Long and Controversial Journey of α-Synuclein
por: Heras-Garvin, Antonio, et al.
Publicado: (2020)

A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy
por: Meissner, Wassilios G., et al.
Publicado: (2020)

Iron-mediated aggregation and toxicity in a novel neuronal cell culture model with inducible alpha-synuclein expression
por: Bartels, Martin, et al.
Publicado: (2019)

The Concept of α-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders
por: Malfertheiner, Katja, et al.
Publicado: (2021)

Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
por: Galabova, Gergana, et al.
Publicado: (2014)

ANL/WSU radiation damage studies
por: Jankowski, D, et al.
Publicado: (1993)

Neutrino interactions at ANL, BNL, and CERN
por: Musset, P
Publicado: (1974)

L'approche neurolinguistique (ANL) : foire aux questions /
por: Germain, Claude
Publicado: (2017)

Signs of Chronic Hypoxia Suggest a Novel Pathophysiological Event in α‐Synucleinopathies
por: Heras‐Garvin, Antonio, et al.
Publicado: (2020)

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
por: Landlinger, Christine, et al.
Publicado: (2017)

Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model
por: Wegrzynowicz, Michal, et al.
Publicado: (2019)

Signs of early cellular dysfunction in multiple system atrophy
por: Herrera‐Vaquero, M., et al.
Publicado: (2020)

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study
por: Poewe, Werner, et al.
Publicado: (2021)

Extended barrel module 0 instrumentation at ANL
por: ANL, group
Publicado: (1998)

AMU-ANL Conference on Direct Energy Conversion
por: Collective
Publicado: (1963)

Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications
por: Schafferer, Simon, et al.
Publicado: (2016)

Atlas Tile Calorimeter ANL master punching die
por: ANL, photos
Publicado: (1996)

[(11)C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates
por: Kuebler, Laura, et al.
Publicado: (2020)

Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization
por: Dominguez-Meijide, Antonio, et al.
Publicado: (2020)

ATLAS Tile calorimeter: ANL module0 submodules construction
por: ANL, photos
Publicado: (1999)

5th ANL/MSU/JINA/INT FRIB Workshop
por: Danielewicz, Pawel
Publicado: (2009)

Comparison of LED and Cs Data Signals for the ANL Optical Test Module
por: Stanek, B, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_4tfs7fes7phbb3c0qonq940ftl